Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alvotech Raises Further Funds After FDA Green Light

Biosimilars Developer Accepts $166m Offer For 10.1m Shares Following US Approval

Executive Summary

Alvotech has announced a share sale that will raise $166m for the biosimilars developer, in the wake of its recent US Food and Drug Administration approval for its AVT02 adalimumab biosimilar, Simlandi.

You may also be interested in...

Who’s Hired? Sandoz Hires New CFO In A Landmark Year

Sandoz has appointed a new CFO as it embarks on its first full year as an independent company. Meanwhile, Alvotech has named a new head of quality and Euroapi has selected a fresh CEO.

Alvotech And Jamp Launch First Stelara Biosimilar In Canada

Alvotech and Jamp have launched Canada’s first Stelara biosimilar, just a couple of weeks after Alvotech disclosed a settlement that would allow its ustekinumab product to be introduced in markets around the world.

Alvotech Clears A Path For 2024 Ustekinumab In Major Global Markets

Alvotech has ensured there won’t be any legal hurdles to overcome as it plots launches via commercialization partners for its AVT04 proposed biosimilar to Stelara in major global markets.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts